Merck Buys Cough Drug Developer for $1.25B
The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
Ex-Merck Analyst Hit with Insider Trading Rap
He allegedly helped a friend make more than $700,000 on insider M&A info.
CFOs on the Move: Week Ended March 28
Merck, AlixPartners, Laboratory Corp. of America, Catamaran, Bell and Howell, Cyan, RealPage, WPX Energy
Transforming Cisco: One Finance Function At a Time
Cisco's shares have made a comeback, and CFO Frank Calderoni says a finance unit revamp was one of the key pieces of the company's turnaround.
Too Much Cash?
Corporate balance sheets are swelling with cash, reaching $1.8 trillion at the end of 2012. Many accuse companies of hoarding, but there’s more to the story.
The Best Medicines
Merck invests billions in drug R&spamp;D every year, and it&spamp;rsquo;s up to CFO Peter Kellogg to ensure that the money is spent wisely.